全球智库信息集成服务系统(G2TT): Mid-Term Assessment of the EU Drugs Strategy 2013–2020 and Final Evaluation of the Action Plan on Drugs 2013

G2TT

来源类型	Research Reports
规范类型	报告
DOI	https://doi.org/10.7249/RR1823
来源ID	RR-1823-EC
	Mid-Term Assessment of the EU Drugs Strategy 2013–2020 and Final Evaluation of the Action Plan on Drugs 2013–2016: Final report
	Emilie Balbirnie; Matthew Davies; Emma Disley; Cristina Gonzalez Monsalve; Stephen Hartka; Stijn Hoorens; Kristy Kruithof; Martin Sacher; Jirka Taylor
发表日期	2016
出版者	RAND Corporation
出版年	2016
页码	151
语种	英语
结论	The majority of the actions in the EU Action Plan on Drugs have been implemented and considerable progress has been made with regards to the 15 objectives in the EU Drugs Strategy. There was widespread agreement about the continued need for an Action Plan, as it's considered to be necessary in translating the EU Drugs Strategy into more precise priorities and actions. The Drugs Strategy and Action Plan were found to be broadly aligned with the objectives set out in other relevant EU and Member State policies and strategies. However, there was scope for greater coherence and coordination in the field of internal security and with key aspects of the EU Health Strategy. The resources available to implement the EU Drugs Strategy and Action Plan were considered to be sufficient, particularly with regard to drug demand and supply. However, stakeholders indicated that increasing resources would ensure the better implementation of actions outlined in the EU Action Plan. The Drugs Strategy provided added value to individual Member States by establishing a common EU-wide strategic framework and developing a process of consensus-building for increasingly complex and international issues. The Strategy and Action Plan appear to add most value in newer Member States, which did not have pre-existing or developed drugs policies prior to their EU accession. The Strategy also added value by guiding drug policy and cooperation with countries outside of Europe, allowing Member States to 'speak with one voice' in international fora.
摘要	The evaluation made 20 recommendations, addressed to the European Commission, Member States, the European Council and other stakeholders. The key recommendation was that the European Commission should propose a new Action Plan for the period 2017–2020 in order to continue translating the high-level objectives into concrete action. It was recommended that the new Action Plan should be an updated version of the current one rather than taking on a new approach or introducing more actions.
主题	Drug Markets and Supply ; Drug Policy and Trends ; European Union ; Illegal Drug Trade ; Substance Abuse Prevention
URL	https://www.rand.org/pubs/research_reports/RR1823.html
来源智库	RAND Corporation (United States)
引用统计
资源类型	智库出版物
条目标识符	http://119.78.100.153/handle/2XGU8XDN/108376
推荐引用方式 GB/T 7714	Emilie Balbirnie,Matthew Davies,Emma Disley,等. Mid-Term Assessment of the EU Drugs Strategy 2013–2020 and Final Evaluation of the Action Plan on Drugs 2013–2016: Final report. 2016.

条目包含的文件
文件名称/大小	资源类型	版本类型	开放类型	使用许可
x1495722223421.jpg（5KB）	智库出版物		限制开放	CC BY-NC-SA	浏览
RAND_RR1823.pdf（1028KB）	智库出版物		限制开放	CC BY-NC-SA	浏览